305 related articles for article (PubMed ID: 23543271)
1. A phase I study investigating the safety and pharmacokinetics of highly bioavailable curcumin (Theracurmin) in cancer patients.
Kanai M; Otsuka Y; Otsuka K; Sato M; Nishimura T; Mori Y; Kawaguchi M; Hatano E; Kodama Y; Matsumoto S; Murakami Y; Imaizumi A; Chiba T; Nishihira J; Shibata H
Cancer Chemother Pharmacol; 2013 Jun; 71(6):1521-30. PubMed ID: 23543271
[TBL] [Abstract][Full Text] [Related]
2. Dose-escalation and pharmacokinetic study of nanoparticle curcumin, a potential anticancer agent with improved bioavailability, in healthy human volunteers.
Kanai M; Imaizumi A; Otsuka Y; Sasaki H; Hashiguchi M; Tsujiko K; Matsumoto S; Ishiguro H; Chiba T
Cancer Chemother Pharmacol; 2012 Jan; 69(1):65-70. PubMed ID: 21603867
[TBL] [Abstract][Full Text] [Related]
3. Safety and efficacy of single-day GemOx regimen in patients with pancreatobiliary cancer: a single institution experience.
Li J; Merl M; Lee MX; Kaley K; Saif MW
Expert Opin Drug Saf; 2010 Mar; 9(2):207-13. PubMed ID: 20095915
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic applications of curcumin for patients with pancreatic cancer.
Kanai M
World J Gastroenterol; 2014 Jul; 20(28):9384-91. PubMed ID: 25071333
[TBL] [Abstract][Full Text] [Related]
5. Colloidal submicron-particle curcumin exhibits high absorption efficiency-a double-blind, 3-way crossover study.
Sunagawa Y; Hirano S; Katanasaka Y; Miyazaki Y; Funamoto M; Okamura N; Hojo Y; Suzuki H; Doi O; Yokoji T; Morimoto E; Takashi T; Ozawa H; Imaizumi A; Ueno M; Kakeya H; Shimatsu A; Wada H; Hasegawa K; Morimoto T
J Nutr Sci Vitaminol (Tokyo); 2015; 61(1):37-44. PubMed ID: 25994138
[TBL] [Abstract][Full Text] [Related]
6. Phase I clinical trial of the novel platin complex dicycloplatin: clinical and pharmacokinetic results.
Li S; Huang H; Liao H; Zhan J; Guo Y; Zou BY; Jiang WQ; Guan ZZ; Yang XQ
Int J Clin Pharmacol Ther; 2013 Feb; 51(2):96-105. PubMed ID: 23127487
[TBL] [Abstract][Full Text] [Related]
7. Phase II trial of curcumin in patients with advanced pancreatic cancer.
Dhillon N; Aggarwal BB; Newman RA; Wolff RA; Kunnumakkara AB; Abbruzzese JL; Ng CS; Badmaev V; Kurzrock R
Clin Cancer Res; 2008 Jul; 14(14):4491-9. PubMed ID: 18628464
[TBL] [Abstract][Full Text] [Related]
8. Highly absorptive curcumin reduces serum atherosclerotic low-density lipoprotein levels in patients with mild COPD.
Funamoto M; Sunagawa Y; Katanasaka Y; Miyazaki Y; Imaizumi A; Kakeya H; Yamakage H; Satoh-Asahara N; Komiyama M; Wada H; Hasegawa K; Morimoto T
Int J Chron Obstruct Pulmon Dis; 2016; 11():2029-34. PubMed ID: 27616885
[TBL] [Abstract][Full Text] [Related]
9. Short-term effects of highly-bioavailable curcumin for treating knee osteoarthritis: a randomized, double-blind, placebo-controlled prospective study.
Nakagawa Y; Mukai S; Yamada S; Matsuoka M; Tarumi E; Hashimoto T; Tamura C; Imaizumi A; Nishihira J; Nakamura T
J Orthop Sci; 2014 Nov; 19(6):933-9. PubMed ID: 25308211
[TBL] [Abstract][Full Text] [Related]
10. Innovative preparation of curcumin for improved oral bioavailability.
Sasaki H; Sunagawa Y; Takahashi K; Imaizumi A; Fukuda H; Hashimoto T; Wada H; Katanasaka Y; Kakeya H; Fujita M; Hasegawa K; Morimoto T
Biol Pharm Bull; 2011; 34(5):660-5. PubMed ID: 21532153
[TBL] [Abstract][Full Text] [Related]
11. Phase I study of the botanical formulation PHY906 with capecitabine in advanced pancreatic and other gastrointestinal malignancies.
Saif MW; Lansigan F; Ruta S; Lamb L; Mezes M; Elligers K; Grant N; Jiang ZL; Liu SH; Cheng YC
Phytomedicine; 2010 Mar; 17(3-4):161-9. PubMed ID: 20092990
[TBL] [Abstract][Full Text] [Related]
12. Potential protective effect of highly bioavailable curcumin on an oxidative stress model induced by microinjection of sodium nitroprusside in mice brain.
Nazari QA; Takada-Takatori Y; Hashimoto T; Imaizumi A; Izumi Y; Akaike A; Kume T
Food Funct; 2014 May; 5(5):984-9. PubMed ID: 24637610
[TBL] [Abstract][Full Text] [Related]
13. Comparative pharmacokinetics of Theracurmin, a highly bioavailable curcumin, in healthy adult subjects.
Chung H; Yoon SH; Cho JY; Yeo HK; Shin D; Park JY
Int J Clin Pharmacol Ther; 2021 Oct; 59(10):684-690. PubMed ID: 34423771
[TBL] [Abstract][Full Text] [Related]
14. Early phase II study of uracil-tegafur plus doxorubicin in patients with unresectable advanced biliary tract cancer.
Furuse J; Okusaka T; Funakoshi A; Yamao K; Nagase M; Ishii H; Nakachi K; Ueno H; Ikeda M; Morizane C; Horikawa Y; Mizuno N
Jpn J Clin Oncol; 2006 Sep; 36(9):552-6. PubMed ID: 16887837
[TBL] [Abstract][Full Text] [Related]
15. Oral paclitaxel and concurrent cyclosporin A: targeting clinically relevant systemic exposure to paclitaxel.
Britten CD; Baker SD; Denis LJ; Johnson T; Drengler R; Siu LL; Duchin K; Kuhn J; Rowinsky EK
Clin Cancer Res; 2000 Sep; 6(9):3459-68. PubMed ID: 10999729
[TBL] [Abstract][Full Text] [Related]
16. Phase II study of capecitabine and cisplatin in previously untreated advanced biliary tract cancer.
Hong YS; Lee J; Lee SC; Hwang IG; Choi SH; Heo JS; Park JO; Park YS; Lim HY; Kang WK
Cancer Chemother Pharmacol; 2007 Aug; 60(3):321-8. PubMed ID: 17143602
[TBL] [Abstract][Full Text] [Related]
17. [Current aspects of chemotherapy of metastatic pancreatic and biliary tract carcinomas].
Bokemeyer C; Kollmannsberger C; Oettle H; Kanz L
Praxis (Bern 1994); 2000 Sep; 89(39):1545-52. PubMed ID: 11068508
[TBL] [Abstract][Full Text] [Related]
18. Capecitabine and celecoxib as second-line treatment of advanced pancreatic and biliary tract cancers.
Pino MS; Milella M; Gelibter A; Sperduti I; De Marco S; Nuzzo C; Bria E; Carpanese L; Ruggeri EM; Carlini P; Cognetti F
Oncology; 2009; 76(4):254-61. PubMed ID: 19246950
[TBL] [Abstract][Full Text] [Related]
19. Determination of minimum effective dose and optimal dosing schedule for liposomal curcumin in a xenograft human pancreatic cancer model.
Mach CM; Mathew L; Mosley SA; Kurzrock R; Smith JA
Anticancer Res; 2009 Jun; 29(6):1895-9. PubMed ID: 19528445
[TBL] [Abstract][Full Text] [Related]
20. [Noble Heart Failure Therapy Using Food Compositions].
Morimoto T; Funamoto M; Sunagawa Y; Katanasaka Y; Miyazaki Y; Hasegawa K
Yakugaku Zasshi; 2018; 138(10):1263-1269. PubMed ID: 30270270
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
